{"id":518812,"date":"2021-07-28T07:13:02","date_gmt":"2021-07-28T11:13:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/"},"modified":"2021-07-28T07:13:02","modified_gmt":"2021-07-28T11:13:02","slug":"acceleron-announces-second-quarter-2021-reblozyl-net-sales","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/","title":{"rendered":"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales"},"content":{"rendered":"

<\/p>\n

Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae<\/sup> Net Sales<\/b><\/p>\n

– Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL\u00ae<\/sup> (luspatercept-aamt) as reported by Bristol Myers Squibb –<\/i><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nAcceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL\u00ae<\/sup><\/i>(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021.\n<\/p>\n

\nAcceleron expects to report royalty revenue of approximately $25.6 million from net sales of REBLOZYL in the second quarter ended June 30, 2021. This compares with approximately $22.4 million in royalty revenue from approximately $112 million of net sales of REBLOZYL for the first quarter ended March 31, 2021.\n<\/p>\n

\nThe preliminary unaudited revenue estimate for the quarter ended June 30, 2021 included in this release is the responsibility of management and is subject to the completion of the Company\u2019s customary quarter-end financial closing procedures, including management\u2019s review and finalization, as well as review procedures by the Company\u2019s independent registered public accounting firm, which have not yet been completed. During the course of the Company\u2019s review process, items may be identified that would require it to make adjustments, which could result in material changes to the Company\u2019s preliminary unaudited estimated financial results. Consequently, this revenue estimate should not be viewed as a substitute for the Company\u2019s earnings release and Quarterly Report on Form 10-Q.\n<\/p>\n

About Acceleron<\/b><\/p>\n

\nAcceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron\u2019s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.\n<\/p>\n

\nAcceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary hypertension (PH). Following positive PULSAR Phase 2 results, Acceleron is executing on its Phase 3 development plan to support its long-term vision of establishing sotatercept as a backbone therapy for patients with pulmonary arterial hypertension (PAH) at all stages of the disease. Acceleron is also expanding the development of sotatercept into Group 2 PH, with the CADENCE Phase 2 trial expected to initiate this year. Acceleron has expanded its rare pulmonary disease pipeline and is investigating the potential of ACE-1334 in a Phase 1b\/Phase 2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD).\n<\/p>\n

\nIn hematology, REBLOZYL\u00ae<\/sup> (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.\n<\/p>\n

\nFor more information, please visit www.acceleronpharma.com<\/a>. Follow Acceleron on Social Media: @AcceleronPharma<\/a> and LinkedIn<\/a>.\n<\/p>\n

Cautionary Note on Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements about the Company’s financial results. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.\n<\/p>\n

\nActual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of the Company’s compounds and data from clinical trials may not be predictive of the results or success of other clinical trials, that regulatory approval of the Company\u2019s compounds in one indication or country may not be predictive of approval in another indication or country, that the development of the Company\u2019s compounds may take longer and\/or cost more than planned or accelerate faster than currently expected, that the Company or its collaboration partner, Bristol Myers Squibb (\u201cBMS\u201d), may be unable to successfully complete the clinical development of the Company\u2019s compounds, that the Company or BMS may be delayed in initiating, enrolling or completing any clinical trials, and that the Company\u2019s compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading \u201cRisk Factors\u201d included in the Company\u2019s most recent Annual Report on Form 10-K and other filings that the Company has made and may make with the SEC in the future.\n<\/p>\n

\nThe forward-looking statements contained in this press release are based on management’s current views, plans, estimates, assumptions, and projections with respect to future events, and the Company does not undertake and specifically disclaims any obligation to update any forward-looking statements.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210728005487\/en\/<\/a><\/span><\/p>\n

\nAcceleron Pharma Inc.\n<\/p>\n

\nInvestors:
\n
Jamie Bernard, IRC, 617-301-9650
\n
Associate Director, Investor Relations\n<\/p>\n

\nMedia:
\n
Matt Fearer, 617-301-9557
\n
Senior Director, Corporate Communications\n<\/p>\n

KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Genetics Research Pharmaceutical Science Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales – Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL\u00ae (luspatercept-aamt) as reported by Bristol Myers Squibb – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL\u00ae(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021. Acceleron expects to report royalty revenue of approximately $25.6 million from net sales of REBLOZYL in the second quarter ended June 30, 2021. This compares with approximately … <\/p>\n

Continue reading “Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-518812","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAcceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales – Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL\u00ae (luspatercept-aamt) as reported by Bristol Myers Squibb – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL\u00ae(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021. Acceleron expects to report royalty revenue of approximately $25.6 million from net sales of REBLOZYL in the second quarter ended June 30, 2021. This compares with approximately … Continue reading "Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-28T11:13:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales\",\"datePublished\":\"2021-07-28T11:13:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/\"},\"wordCount\":841,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/\",\"name\":\"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-28T11:13:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/","og_locale":"en_US","og_type":"article","og_title":"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales - Market Newsdesk","og_description":"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales – Acceleron expects to report approximately $25.6 million in royalty revenue for Q2 2021 from approximately $128 million in net sales of REBLOZYL\u00ae (luspatercept-aamt) as reported by Bristol Myers Squibb – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced net sales of REBLOZYL\u00ae(luspatercept-aamt) as reported by its global collaborator, Bristol Myers Squibb, were approximately $128 million for the second quarter ended June 30, 2021. Acceleron expects to report royalty revenue of approximately $25.6 million from net sales of REBLOZYL in the second quarter ended June 30, 2021. This compares with approximately … Continue reading \"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-28T11:13:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales","datePublished":"2021-07-28T11:13:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/"},"wordCount":841,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/","name":"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-28T11:13:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210728005487r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acceleron-announces-second-quarter-2021-reblozyl-net-sales\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Acceleron Announces Second Quarter 2021 REBLOZYL\u00ae Net Sales"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/518812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=518812"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/518812\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=518812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=518812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=518812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}